323 377

Cited 0 times in

SARS-CoV-2 Variants of Concern

DC Field Value Language
dc.contributor.author최준용-
dc.date.accessioned2021-12-28T17:26:19Z-
dc.date.available2021-12-28T17:26:19Z-
dc.date.issued2021-11-
dc.identifier.issn0513-5796-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/187099-
dc.description.abstractSince the COVID-19 pandemic first began in December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has continuously evolved with many variants emerging across the world. These variants are categorized as the variant of interest (VOI), variant of concern (VOC), and variant under monitoring (VUM). As of September 15, 2021, there are four SARS-CoV-2 lineages designated as the VOC (alpha, beta, gamma, and delta variants). VOCs have increased transmissibility compared to the original virus, and have the potential for increasing disease severity. In addition, VOCs exhibit decreased susceptibility to vaccine-induced and infection-induced immune responses, and thus possess the ability to reinfect previously infected and recovered individuals. Given their ability to evade immune responses, VOC are less susceptible to monoclonal antibody treatments. VOCs can also impact the effectiveness of mRNA and adenovirus vector vaccines, although the currently authorized COVID-19 vaccines are still effective in preventing infection and severe disease. Current measures to reduce transmission as well as efforts to monitor and understand the impact of variants should be continued. Here, we review the molecular features, epidemiology, impact on transmissibility, disease severity, and vaccine effectiveness of VOCs.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherYonsei University-
dc.relation.isPartOfYONSEI MEDICAL JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleSARS-CoV-2 Variants of Concern-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorJun Yong Choi-
dc.contributor.googleauthorDavey M. Smith-
dc.identifier.doi10.3349/ymj.2021.62.11.961-
dc.contributor.localIdA04191-
dc.relation.journalcodeJ02813-
dc.identifier.eissn1976-2437-
dc.identifier.pmid34672129-
dc.subject.keywordSARS-CoV-2-
dc.subject.keywordCOVID-19-
dc.subject.keywordvariant-
dc.subject.keywordvariant of concern-
dc.subject.keyworddelta variant-
dc.subject.keywordalpha variant-
dc.subject.keywordvaccine-
dc.contributor.alternativeNameChoi, Jun Yong-
dc.contributor.affiliatedAuthor최준용-
dc.citation.volume62-
dc.citation.number11-
dc.citation.startPage961-
dc.citation.endPage968-
dc.identifier.bibliographicCitationYONSEI MEDICAL JOURNAL, Vol.62(11) : 961-968, 2021-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.